On November 2, 2020 Seagen Inc. (Nasdaq: SGEN) reported that it will host a virtual R&D day for investors and analysts on Monday, November 16, 2020 beginning at 10:00 a.m. Eastern Time (Press release, Seagen, NOV 2, 2020, View Source [SID1234569657]). The program will include a presentation by members of Seagen leadership on the broad clinical development of the Company’s marketed products, ADCETRIS (brentuximab vedotin), PADCEV (enfortumab vedotin-ejfv) and TUKYSA (tucatinib), and its deep pipeline of innovative therapies for cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Access to the event will be available at the Company’s website www.seagen.com in the Investors section. A replay will be archived on the Company’s website following the live presentation.